Learn more about Janssen’s COVID-19 response and our continued support to help patients afford and access our medicines.[x]

Contact Us

We are happy to answer your questions.

For any questions regarding treatment with CONCERTA®, please call

1-800-JANSSEN (1-800-526-7736)

Monday through Friday from 9:00 AM to 8:00 PM ET

Thank you.

IMPORTANT SAFETY INFORMATION

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs. Keep CONCERTA® in a safe place to prevent misuse and abuse.

Who should not take CONCERTA®?

CONCERTA® should not be taken by patients who have:

  • allergies to methylphenidate or other ingredients in CONCERTA®
  • significant anxiety, tension or agitation
  • glaucoma
  • tics, Tourette’s syndrome or family history of Tourette’s syndrome
  • current or past use of monoamine oxidase inhibitor (MAOI)
  • esophagus, stomach or intestinal narrowing

Children under 6 years of age should not take CONCERTA®.

Tell your healthcare professional if you or your child has had:

  • any heart problems, heart defects, high blood pressure or a family history of these problems
  • has had depression, abnormal thoughts or visions, bipolar disorder, or seizures
  • numbness, pain, skin color change or sensitivity to temperature in fingers or toes

Contact your healthcare professional immediately if you or your child:

  • develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity
  • if aggressive behavior or hostility develops or worsens while taking CONCERTA®

Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop priapism, seek medical help right away. Because of the potential for lasting damage, priapism should be evaluated by a doctor immediately.

Your child’s healthcare professional should check height and weight often and may interrupt CONCERTA® treatment if your child is not growing or gaining weight as expected.

Stimulants may impair the ability of a patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA® does not adversely affect your ability to engage in such activities.

The most common adverse reactions in double-blind clinical trials (>5%) reported:

  • in children and adolescents was upper abdominal pain
  • in adult patients were decreased appetite, headache, dry mouth, nausea, trouble sleeping, anxiety, dizziness, weight decreased, irritability and increased sweating

CONCERTA® is a registered trademark of ALZA Corporation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the full Prescribing Information including Boxed WARNING and the Medication Guide for CONCERTA®.

cp-180018v1

INDICATION

CONCERTA® (methylphenidate HCl) Extended-release Tablets CII is a prescription medication approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

IMPORTANT SAFETY INFORMATION

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs. Keep CONCERTA® in a safe place to prevent misuse and abuse.

Who should not take CONCERTA®?

CONCERTA® should not be taken by patients who have:

  • allergies to methylphenidate or other ingredients in CONCERTA®
  • significant anxiety, tension or agitation
  • glaucoma
  • tics, Tourette’s syndrome or family history of Tourette’s syndrome
  • current or past use of monoamine oxidase inhibitor (MAOI)
  • esophagus, stomach or intestinal narrowing

Children under 6 years of age should not take CONCERTA®.

Tell your healthcare professional if you or your child has had:

  • any heart problems, heart defects, high blood pressure or a family history of these problems
  • has had depression, abnormal thoughts or visions, bipolar disorder, or seizures
  • numbness, pain, skin color change or sensitivity to temperature in fingers or toes

Contact your healthcare professional immediately if you or your child:

  • develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity
  • if aggressive behavior or hostility develops or worsens while taking CONCERTA®

Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop priapism, seek medical help right away. Because of the potential for lasting damage, priapism should be evaluated by a doctor immediately.

Your child’s healthcare professional should check height and weight often and may interrupt CONCERTA® treatment if your child is not growing or gaining weight as expected.

Stimulants may impair the ability of a patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA® does not adversely affect your ability to engage in such activities.

The most common adverse reactions in double-blind clinical trials (>5%) reported:

  • in children and adolescents was upper abdominal pain
  • in adult patients were decreased appetite, headache, dry mouth, nausea, trouble sleeping, anxiety, dizziness, weight decreased, irritability and increased sweating

CONCERTA® is a registered trademark of ALZA Corporation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the full Prescribing Information including Boxed WARNING and the Medication Guide for CONCERTA®.

cp-180018v1

+
INDICATION

CONCERTA® (methylphenidate HCl) Extended-release Tablets CII is a prescription medication approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.